Price
$1.39
Decreased by -0.71%
Dollar volume (20D)
1.86 M
ADR%
6.76
Earnings report date
May 13, 2025
Shares float
109.66 M
Shares short
12.19 M [11.12%]
Shares outstanding
199.80 M
Market cap
277.72 M
Beta
1.23
Price/earnings
N/A
20D range
1.19 1.56
50D range
1.15 1.75
200D range
1.03 2.56

Atai Life SciencesN. V., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada.

The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic in Phase 2a trial for the treatment of major depressive disorder.

It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists in preclinical studies for TRD.

In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders.

ATAI Life SciencesN. V. was founded in 2018 and is headquartered in Berlin, Germany.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
Mar 26, 25 -0.24
Decreased by -100.00%
-0.15
Decreased by -60.00%
Nov 5, 24 -0.16
Increased by +42.86%
-0.16
Aug 6, 24 -0.36
Decreased by -71.43%
-0.16
Decreased by -125.00%
May 15, 24 -0.17
Increased by +19.05%
-0.18
Increased by +5.56%
Mar 28, 24 -0.12
Increased by +57.14%
-0.16
Increased by +25.00%
Nov 14, 23 -0.28
Decreased by -27.27%
-0.20
Decreased by -40.00%
Aug 10, 23 -0.21
Increased by +12.50%
-0.21
May 11, 23 -0.21
Increased by +12.50%
-0.21
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Dec 31, 24 -5.00 K
Decreased by -127.78%
-38.96 M
Decreased by -112.98%
Increased by +779.16 K%
Increased by +866.72%
Sep 30, 24 40.00 K
Decreased by -54.02%
-26.29 M
Decreased by -159.41%
Decreased by -65.72 K%
Decreased by -229.22%
Jun 30, 24 273.00 K
Increased by +58.72%
-57.31 M
Decreased by -73.45%
Decreased by -20.99 K%
Decreased by -9.28%
Mar 31, 24 0.00
Decreased by -100.00%
-26.71 M
Increased by +19.83%
Decreased by N/A%
Decreased by N/A%
Dec 31, 23 18.00 K
Decreased by -52.63%
-18.29 M
Increased by +59.64%
Decreased by -101.62 K%
Increased by +14.80%
Sep 30, 23 87.00 K
Increased by +262.50%
44.24 M
Increased by +232.99%
Increased by +50.86 K%
Increased by +136.69%
Jun 30, 23 172.00 K
Increased by +1.18%
-33.04 M
Decreased by -7.08%
Decreased by -19.21 K%
Decreased by -5.84%
Mar 31, 23 37.00 K
Increased by +N/A%
-33.32 M
Decreased by -4.25%
Decreased by -90.06 K%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY